Skip to main content

Table 1 Treatment groups

From: Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct

Group Treatment
Mock Normal saline (NS) was administered as control
shScr-V VNP20009 carrying the scrambled shRNA construct was administered
shSox2-V VNP20009 carrying the Sox2 shRNA construct was administered
HM-3 HM-3 was administered
HM-3 + shScr-V Both HM-3 and shScr-V were administered
HM-3 + shSox2-V Both HM-3 and shSox2-V were administered
Docetaxel Docetaxel was administered